TSE:4568Pharmaceuticals
The Bull Case For Daiichi Sankyo Company (TSE:4568) Could Change Following ENHERTU’s Priority Review Success
In March 2026, Daiichi Sankyo and AstraZeneca announced that the U.S. FDA accepted and granted Priority Review to their supplemental Biologics License Application for ENHERTU, targeting adults with HER2 positive breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment.
The application rests on DESTINY-Breast05 phase 3 data showing ENHERTU cut the risk of invasive disease recurrence or death versus T-DM1, with three-year invasive disease-free survival of...